Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment

Oral Neoplasm

Leukoplakia, Erythroplakia, Erythroleukoplakia, Lesion, Oral Epithelial Dysplasia, S100A7 Biomarker, S100A7 Immunohistochemistry Signature-based, Early Diagnosis, STRATICYTE, Oral Neoplasia, Oral Epithelial Atypia, Hyperplasia, Hyperkeratosis, Oral Squamous Cell Carcinoma, Oral Cancer, Potentially Premalignant Oral Epithelial Lesion, OPMD, Mild Dysplasia, Moderate Dysplasia, Severe Dysplasia, Low-grade Dysplasia, High-grade Dysplasia, Personalized Medicine, Predictive Assay, Whole Slide Imaging, Computational Pathology, Digital Pathology, Artificial Intelligence, Machine Learning, OPML, Oral Potentially Malignant Disorder, Oral Potentially Malignant Lesion

The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.

Background: The standard of care for potentially premalignant oral epithelial lesion (PPOEL) risk assessment for progression to cancer is dysplasia grading by histopathology. With significant overlap between dysplasia grades and high inter- and intra-observer variations, dysplasia grading alone has been shown to be inadequate as a prognostic tool. To investigate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in the early diagnosis of invasive oral cancer, a prospective multi-center observational study was designed with specimens obtained from community-based practices. Methods: Patients that qualify to enroll in the study will be assessed for both standard of care histopathological assessment for dysplasia grade and STRATICYTE risk assessment, and followed for up to 60 months (from initial biopsy) to determine the outcome of their oral lesion(s).

No related papers found yet.

Canada